Dare Bioscience Business Summary

Daré Bioscience, Inc. (DARE) is a clinical-to-commercial stage biopharmaceutical company that generates revenue through a multi-channel strategy including strategic licensing agreements, royalty monetization, and a proprietary "dual-path" commercialization model. The company’s primary business segments focus on women’s reproductive health, specifically contraception, sexual health, and vaginal health. Revenue is currently driven by the global licensing of XACIATO to Organon and a $22 million royalty monetization deal with XOMA, supplemented by the 2026 rollout of products like DARE to PLAY™ (Sildenafil Cream) via the 503B compounding pathway and DARE to RESTORE™ vaginal probiotics in the consumer health market. Within the competitive landscape, Daré contends with players such as Anixa Biosciences, Evofem Biosciences, and Agile Therapeutics, positioning itself as a purpose-driven leader that bridges the gap between clinical innovation and real-world access in underserved women’s health categories. Founded by CEO Sabrina Martucci Johnson and former CFO Lisa Walters-Hoffert, the leadership team brings deep pedigree from established life science firms. Johnson, who also serves as the company's principal financial officer, previously held executive roles at WomanCare Global and Cypress Bioscience. The technical pipeline is overseen by Chief Scientific Officer David Friend, Ph.D., while the board is chaired by William H. Rastetter, Ph.D., a notable industry veteran who co-founded Receptos and formerly served as Chairman of Illumina. The company is backed by a high-profile roster of institutional investors and advisors, including Polaris Partners (represented by major shareholder Alan Crane), Venrock Associates, and Eli Lilly & Co., with renowned MIT professor and biotech pioneer Robert S. Langer serving on its Scientific Advisory Board.